Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeableHaemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) in Mexican infants
| Autor: | M. Lourdes Guerrero, Marta Moreira, Abigail Casas-Muñoz, Yolanda Cervantes-Apolinar, Antonio Lavalle-Villalobos, Guillermo M. Ruiz-Palacios, Lorena Hernández-Delgado, Lode Schuerman |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Serotype Haemophilus Infections Lipoproteins Immunology medicine.disease_cause Pneumococcal Infections Pneumococcal conjugate vaccine Haemophilus influenzae Pneumococcal Vaccines Bacterial Proteins Phagocytosis Conjugate vaccine Human rotavirus medicine Humans Hepatitis B Vaccines Vaccines Combined Serotyping General Pharmacology Toxicology and Pharmaceutics Mexico Diphtheria-Tetanus-Pertussis Vaccine Immunization Schedule Haemophilus Vaccines Vaccines Conjugate Reactogenicity business.industry Immunogenicity Rotavirus Vaccines Infant Immunoglobulin D Opsonin Proteins Antibodies Bacterial Virology Poliovirus Vaccine Inactivated Streptococcus pneumoniae Treatment Outcome Pneumococcal vaccine Female Carrier Proteins business medicine.drug |
| Zdroj: | Human Vaccines. 7:1137-1145 |
| ISSN: | 1554-8619 1554-8600 |
| DOI: | 10.4161/hv.7.11.17984 |
| Popis: | The immunogenicity and safety of the 10-valent pneumococcal conjugate vaccine, PHiD-CV, have been documented in European and Asian studies. In this open study conducted in Mexico (NCT00489554), 230 healthy infants received three doses of PHiD-CV and DTPa-HBV-IPV/Hib vaccines at 2, 4 and 6 months of age and two doses of oral human rotavirus vaccine at 2 and 4 months. Serotype-specific pneumococcal responses and opsonophagocytic activity (OPA) were measured one month post-dose 3. PHiD-CV's primary vaccination course was highly immunogenic against each of the 10 pneumococcal vaccine serotypes and carrier protein D. Antibody responses against pneumococcal serotypes and protein D were generally higher in Mexican infants compared with European antibody responses, and functional OPA responses were also higher or in the same range. The most frequent solicited local symptom was pain, with high but similar incidences of grade 3 pain reported at both injection sites (up to 15% of all doses). PHiD-CV was well tolerated, with no serious adverse events considered as causally related to vaccination. Most solicited symptoms were mild and there was no increase in incidence of solicited symptoms with successive vaccine doses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|